Europe’s medicines regulator has added an extremely rare nerve-damaging disorder, Guillain-Barr syndrome, as a possible side-effect of AstraZeneca’s COVID-19 vaccine, regular safety updates from the watchdog showed. The European Medicines Agency said a causal relationship between GBS and the AstraZeneca shot, known as Vaxzevria, was a “at least a reasonable possibility” after 833 cases of GBS were reported out of 592 million doses of the vaccine given worldwide by July 31.
Read more on CDE News